

Characteristics of the 112 individual trials (2019 update)

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown ^a
ARCHER 1009, 2014	Erlotinib	439	62	277	88	331	403	128	46	357	281	395
ARCHER 1009, 2014	Dacomitinib	439	64	288	91	335	400	115	42	360	256	392
ARQ 197-209, 2011	Erlotinib	83	62	49			72	24	0	65	51	72
ARQ 197-209, 2011	Erlotinib+Tivantinib	84	64	51			76	31	1	67	50	78
ATTENTION, 2015	Erlotinib+Tivantinib	154	63	109	154	0	118	0	0	113	92	154
ATTENTION, 2015	Erlotinib	153	63	102	153	0	115	0	0	114	90	153
Bergqvist, 2014	Docetaxel	41	58	31			40	20	1			41
Bergqvist, 2014	AXL1717	58	57	40			52	29	3			58
Besse, 2014	Erlotinib+Everolimus	66	60	36	7	54	64	10	0	61	51	66
Besse, 2014	Erlotinib	67	60	33	2	57	63	10	0	64	41	67
BeTa, 2011	Erlotinib	317	65	170	18	257		17	20	284	317	299
BeTa, 2011	Erlotinib+Bevacizumab	319	65	171	23	264		11	23	285	319	307
Bhatnagar, 2012	Docetaxel	15	57	11	15	0	11	8	2	12	15	15
Bhatnagar, 2012	Gefitinib	15	58	12	15	0	12	9	3	12	15	15
Blumenschein, 2015	Docetaxel	45	61	23	10	35		1	1	38	45	KRAS
Blumenschein, 2015	Trametinib	89	61	46	11	74		0	0	83	89	KRAS
BR21, 2005	Placebo	243	59	160	28	188		78	56	201	121	175
BR21, 2005	Erlotinib	488	62	315	63	379		144	126	384	243	371
CALGB 30704, 2014	Pemetrexed+Sunitinib	41	63	22	1	32	38	6	0		39	41
CALGB 30704, 2014	Pemetrexed	42	63	22	0	36	37	4	0		38	42
CALGB 30704, 2014	Sunitinib	47	63	25	1	43	39	7	0		43	47
CheckMate017, 2015	Nivolumab	135	62	111	4	122	105	135	0	125	135	135
CheckMate017, 2015	Docetaxel	137	64	97	2	130	112	137	0	130	137	137
CheckMate057, 2015	Docetaxel	290	62	168	8	266		0	0	230	259	252
CheckMate057, 2015	Nivolumab	292	61	151	9	267		0	0	234	256	256

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
Chen, 2011	Tegafur/uracil+Gefitinib	57	65	37	57	0		0	11	25	25	37
Chen, 2011	Gefitinib	58	64	33	58	0		0	24	28	31	42
CTONG0806, 2014	Pemetrexed	80	56	47	80	0	66	4	0	36	80	80
CTONG0806, 2014	Gefitinib	81	58	54	81	0	77	2	0	48	81	81
Dai, 2013	Gefitinib	23	62	15	23	0	19	0	6	13	23	23
Dai, 2013	Pemetrexed	23	61	14	23	0	18	0	5	12	23	23
DATE, 2015	Gefitinib+Nimotuzumab	78	63	54				27	3		78	66
DATE, 2015	Gefitinib	77	63	48				27	0		77	62
DELTA, 2014	Erlotinib	150	68	108	150	0	120	29	6	111	121	150
DELTA, 2014	Docetaxel	151	67	107	151	0	122	32	6	114	130	151
Dittrich, 2014	Pemetrexed+Erlotinib	79	64	46	1	75	64	0	9	69	79	79
Dittrich, 2014	Pemetrexed	83	60	49	1	82	70	0	11	69	83	83
E1512, 2015	Cabozantinib	40	66	14	0	33	24	0	4	34	23	38
E1512, 2015	Erlotinib	42	66	18	2	32	29	0	5	37	23	38
E1512, 2015	Erlotinib+Cabozantinib	43	64	18	0	31	25	0	4	37	21	35
Esteban, 2003	Docetaxel	35	55	29			35	13	12		27	35
Esteban, 2003	Paclitaxel	36	62	30			36	10	13		25	36
Gerber, 2014*	Erlotinib+Tivantinib	51	63	17							22	51
Gerber, 2014*	Chemotherapy	45	65	15							20	45
GFPC 05-06, 2011	Docetaxel	75	59	64			59	23	5		78	75
GFPC 05-06, 2011	Pemetrexed	75	58	62			62	18	4		75	75
Groen, 2013	Erlotinib+Sunitinib	65	59	39	1	63	63	15	0	58	39	61
Groen, 2013	Erlotinib	67	61	45	2	64	67	19	1	58	46	66
Hainsworth, 2010	Selumetinib	40	62	26	0	39		25		34	31	40
Hainsworth, 2010	Pemetrexed	44	64	27	1	42		24		32	35	44
Han, 2011	Docetaxel	40	50	22	40	0		16	4		40	40
Han, 2011	Pemetrexed	44	50	26	44	0		18	6		44	44

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
HANSHIN OncologyGroup 0110, 2015	Docetaxel+Bevacizumab	45	64	27	45	0	36	0	0	34	45	30
HANSHIN Oncology Group 0110, 2015	S1+Bevacizumab	45	64	27	45	0	37	0	0	31	45	27
Herbst, 2007*	Erlotinib+Bevacizumab	39	68	17	3	29		0	0	33	39	38
Herbst, 2007*	Chemotherapy	41	65	25	1	31		0	1	35	41	41
Herbst, 2007*	Chemotherapy+Bevacizumab	40	64	23	2	34		0	0	36	40	40
Heymach, 2007	Docetaxel+Vandetanib	42	61	21	0	42	28	12	0	35	42	42
Heymach, 2007	Docetaxel	41	58	27	0	41	28	11	0	37	41	41
Heymach, 2007	Docetaxel+Vandetanib 300	44	60	25	0	44	35	14	0	40	44	44
HORG, 2013	Pemetrexed	178	66	138	0	178	147	36	31	154	101	178
HORG, 2013	Erlotinib	179	65	135	0	179	154	39	18	150	89	179
Hosomi, 2015	Docetaxel+Ramucirumab	79	66	59	76	0		9	0	65	76	76
Hosomi, 2015	Docetaxel	81	65	62	81	0		9	0	67	81	81
ICOGN, 2013	Gefitinib	199	56	114	199	0	162	36	21	97	107	160
ICOGN, 2013	Icotinib	200	56	118	200	0	162	34	26	99	126	171
INTEREST, 2008	Gefitinib	733	61	466	154	550		185	86	585	619	711
INTEREST, 2008	Docetaxel	733	60	488	169	540		176	84	583	610	711
ISEL, 2005	Placebo	563	61	378	107	431	450	187	145	438	274	563
ISEL, 2005	Gefitinib	1129	62	761	235	843	896	399	332	879	549	1129
ISTANA, 2010	Docetaxel	79	58	45	79	0	65	11	5	43	79	79
ISTANA, 2010	Gefitinib	82	57	55	82	0	71	17	6	52	82	82
Janne, 2013	Docetaxel	43	59	20	0	40	42	6	0	38	43	KRAS
Janne, 2013	Docetaxel+Selumetinib	44	60	21	0	41	39	3	0	39	44	KRAS
JMEI, 2004	Pemetrexed	283	59	194	64	207	212	78	30		283	283
JMEI, 2004	Docetaxel	288	57	217	72	206	215	93	34		288	288
Jones, 2008	Topotecan	39	63	23					1		39	39
Jones, 2008	Docetaxel	41	62	23					6		41	41

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
Juan, 2014	Docetaxel+Erlotinib	34	58	31	0	34	30	16	5	32	33	33
Juan, 2014	Erlotinib	36	64	29	0	36	29	13	6	34	35	34
Kapoor, 2015	Gefitinib	54	56	43	54	0	40		17			20
Kapoor, 2015	Docetaxel	53	56	42	53	0	39		17			17
Katakami, 2014	Amrubicin	101	64	66	98	0	81	17	0	75	78	80
Katakami, 2014	Docetaxel	101	64	69	99	0	74	18	0	75	80	82
KCSG-LU08-01, 2012	Pemetrexed	70	64	10	70	0	61	0	6	0	70	46
KCSG-LU08-01, 2012	Gefitinib	71	58	10	71	0	62	0	6	0	71	49
Kelly, 2012	Pralatrexate	100	63	69		74	87	29	0	100		100
Kelly, 2012	Erlotinib	101	62	68		78	84	47	0	101		101
KEYNOTE-010,2015	Pembrolizumab2	344	63	212	73	246		76	3	281	243	316
KEYNOTE-010,2015	Pembrolizumab 10	346	63	213	72	250		80	1	286	235	320
KEYNOTE-010,2015	Docetaxel	343	62	209	72	251		66	2	276	235	317
Kim A, 2012	Pemetrexed+Cetuximab	301	63	173	3	268		76	12		301	301
Kim A, 2012	Pemetrexed	304	64	188	6	265		71	14		304	304
Kim B, 2012	Docetaxel	166	64	93	2	141		51	11		166	166
Kim B, 2012	Docetaxel+Cetuximab	167	64	92	5	146		41	2		167	167
Kim, 2015	Pemetrexed	47	64	33	47	0	44	10	15	33	32	46
Kim, 2015	Gefitinib	48	67	35	48	0	46	9	17	33	30	47
Krzakowski, 2010	Vinflunine	274	62	205			247	100			274	274
Krzakowski, 2010	Docetaxel	277	60	208			248	95			277	277
Kuo, 2013	Docetaxel	6	54	3	6	0		0	1		6	6
Kuo, 2013	Gefitinib	8	67	4	8	0		0	0		8	8
Lee, 2013	Pemetrexed+Erlotinib	78	56	20	58	20	72	0	7	0	78	78
Lee, 2013	Pemetrexed	80	56	35	68	12	68	0	4	0	80	80
Lee, 2013	Erlotinib	82	54	28	76	6	68	0	6	0	82	82
Levy, 2014	Docetaxel	47	60	24		34	45	12	0			47

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
Levy, 2014	Docetaxel+PX-866	48	65	33		39	45	8	0			48
Li, 2010	Docetaxel	48	48	29	48	0	19	27			48	48
Li, 2010	Gefitinib	50	51	30	50	0	21	22			50	50
Li, 2012	Docetaxel	128	56	74	102	0	61	25			102	128
132Li, 2012	Pemetrexed	132	58	67	106	0	70	19			106	132
Li, 2013	Pemetrexed	27	62	14	0	18		0	3	22	27	27
Li, 2013	Pemetrexed+Erlotinib	52	64	23	2	36		0	5	35	52	45
Li, 2014	Erlotinib	61	54	40	61	0	40	0	4	46	61	61
Li, 2014	Pemetrexed	62	55	39	62	0	38	0	3	45	62	62
Liu, 2015	Pemetrexed	56	51	34	56	0		32	11	55	56	56
Liu, 2015	Nab-Paclitaxel	55	52	37	55	0		27	15	55	55	55
LUME-COLUMBUS,2016	Docetaxel+Nintedanib	6	63	4								6
LUME-COLUMBUS,2016	Docetaxel	6	60	5								6
LUME-LUNG 1, 2014	Docetaxel+Nintedanib	655	60	476	116	533	588	276	1	490	655	655
LUME-LUNG 1, 2014	Docetaxel	659	60	479	123	530	605	279	0	498	659	659
LUME-LUNG 2, 2013	Pemetrexed+Nintedanib	353	60	195	103	225	307	3	0	244	353	336
LUME-LUNG 2, 2013	Pemetrexed	360	59	208	106	230	328	2	0	238	360	349
Lux-Lung 8, 2015	Erlotinib	397	64	331	86	311	345	382	1	379	397	397
Lux-Lung 8, 2015	Afatinib	398	65	335	86	312	349	381	3	372	398	398
Maitland, 2014	Cetuximab	20	62	14	0	13		6		18		20
Maitland, 2014	Pemetrexed+Cetuximab	23	55	13	1	17		8		21		23
Marangolo, 2000	Docetaxel	14	64					4			14	14
Marangolo, 2000	Vinorelbine	11	64					6			11	11
MARQUEE, 2013	Erlotinib	522	61	309	5	446	501	0	1	424	348	469
MARQUEE, 2013	Erlotinib+Tivantinib	526	62	310	8	430	499	0	1	425	346	470
MARVEL, 2013	Erlotinib	11	69	5							11	11
MARVEL, 2013	Pemetrexed	12	55	6							12	12

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
METLung, 2014	Erlotinib	249	63	140	37	180		31	3		157	220
METLung, 2014	Erlotinib+Onartuzumab	250	62	140	35	182		40	5		161	222
Moran, 2014	Erlotinib+Dalotuzumab	37	62	27	0	37	33	11	2	33	27	37
Moran, 2014	Erlotinib	38	59	28	2	36	29	6	1	27	20	38
Natale, 2009	Vandetanib	83	63	48			69	16	0	71		83
Natale, 2009	Gefitinib	85	61	52			63	22	0	77		85
NCCTG N0626, 2011	Pemetrexed+Sorafenib	47	62	27			39	0	0			47
NCCTG N0626, 2011	Pemetrexed	51	62	23			45	0	0			51
NCIC CTG BR.26, 2014	Placebo	240	66	120	70	144	212	44	58	155	64	172
NCIC CTG BR.26, 2014	Dacomitinib	480	64	244	141	288	443	63	119	306	133	366
NVALT-10, 2013	Erlotinib	115	64	75			86	40	9	108	115	115
NVALT-10, 2013	Erlotinib+Chemotherapy	116	63	73			94	34	9	107	116	116
OAK,2016	Atezolizumab	613	63	378	124	302		161	0	501	464	553
OAK,2016	Docetaxel	612	64	379	125	296		160	0	516	465	559
Paz-Ares, 2008	Docetaxel	422	63	302	5	381	343		62		422	422
Paz-Ares, 2008	Paclitaxel	427	62	308	5	397	342		57		427	427
POPLAR, 2016	Atezolizumab	144	62	93				49	2	117	93	133
POPLAR, 2016	Docetaxel	143	62	76				48	1	114	96	135
PROSE, 2014*	Chemotherapy	142	64	91			110	16	8	125	142	123
PROSE, 2014*	Erlotinib	143	66	99			121	31	8	122	143	126
Ramalingam, 2011	Erlotinib	57	62	37	0	55	46	12		48	43	54
Ramalingam, 2011	Erlotinib+R15073W	57	62	38	0	56	50	16		52	39	56
Ramalingam, 2011	Erlotinib+R1507 W	58	63	39	0	55	50	15		50	44	56
Ramalingam, 2012	Dacomitinib	94	60	55	23	68		32	19	76	51	75
Ramalingam, 2012	Erlotinib	94	62	56	24	67		33	3	75	63	83
Ramlau, 2006	Topotecan	414	59	311	31	368	308	155	58		414	414
Ramlau, 2006	Docetaxel	415	59	310	39	359	298	181	65		415	415

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
Ramlau, 2012	Docetaxel+Aflibercept	456	60	305	34	411	414	0	21		456	456
Ramlau, 2012	Docetaxel	457	60	300	40	405	410	0	23		457	457
REVEL, 2014	Docetaxel	625	61	415	86	503		171	0	484	625	607
REVEL, 2014	Docetaxel+Ramucirumab	628	62	419	74	526		157	0	519	628	613
Sbar, 2010	Erlotinib	70		50				17		61		70
Sbar, 2010	BMS-690514	71		50				18		61		71
Scagliotti, 2012	Erlotinib+Sunitinib	480	61	297	52	412	438	135	1	384	340	480
Scagliotti, 2012	Erlotinib	480	61	284	51	413	448	135	0	390	340	480
Scagliotti, 2014	Erlotinib	290	62	225	23	238	235	263	54	264		290
Scagliotti, 2014	Erlotinib+Figitumumab	293	62	228	21	249	230	263	56	277		293
Schiller, 2010	Pemetrexed+Matuzumab	49	63	27	0	47	41	17	0		49	49
Schiller, 2010	Pemetrexed	50	61	33	0	47	44	18	0		50	50
Schiller, 2010	Pemetrexed+Matuzumab 800	51	62	35	0	47	42	11	0	51	51	51
SELECT 1,2017	Docetaxel	256	61	145	4	243	246	14	0	235	256	KRAS
SELECT 1,2017	Docetaxel+Selumetinib	254	62	158	1	241	239	14	0	238	254	KRAS
SIGN, 2006	Gefitinib	68	63	47	0	61	41		25	50	68	68
SIGN, 2006	Docetaxel	73	60	51	0	61	41		21	55	73	73
Spigel, 2011	Erlotinib	56	65	26	0	47		17	10	48	28	53
Spigel, 2011	Erlotinib+Sorafenib	112	65	62	0	97		33	13	93	73	110
Spigel, 2012	Erlotinib	67	67	39							43	67
Spigel, 2012	Erlotinib+Pazopanib	134	66	71							64	134
Spigel, 2013	Erlotinib	68	63	42	1	61		20	2	60	46	62
Spigel, 2013	Erlotinib+Onartuzumab	69	64	40	2	61		20	4	59	46	62
Sun, 2013	Docetaxel	104	56	61	104	0	84	25	11	55	104	104
Sun, 2013	Pemetrexed	107	57	73	107	0	81	27	12	57	107	107
TAILOR, 2013	Docetaxel	110	67	73	1	109	103	23	7	80	102	110

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
TAILOR, 2013	Erlotinib	112	66	77	1	108	103	31	9	93	100	109
TALISMAN, 2015	Docetaxel+Erlotinib	37	66	36				37	0	37	37	37
TALISMAN, 2015	Erlotinib	36	68	36				36	1	36	36	36
TAX 317, 2000	Placebo	49	61	32			40		12		37	49
TAX 317, 2000	Docetaxel	55	61	35			40		14		44	55
TITAN, 2012*	Chemotherapy	221	59	160	26	190	170	77	46	177	221	211
TITAN, 2012*	Erlotinib	203	59	161	28	172	162	77	39	173	203	195
TORI L-03, 2013	Erlotinib+Fulvestrant	50										50
TORI L-03, 2013	Erlotinib	50										50
ULTIMATE-IFCT1103,2016	Paclitaxel+Bevacizumab	111	60	78				11	8	102	76	111
ULTIMATE-IFCT1103,2016	Docetaxel	55	60	42				4	4	46	39	55
V15-32, 2008	Docetaxel	244		151	244	0	150	41	10	157	201	244
V15-32, 2008	Gefitinib	245		151	245	0	159	37	11	174	212	245
Wen, 2016	Docetaxel+Tamoxifen	60	58	44	60	0	27	32	0	35	60	60
Wen, 2016	Docetaxel	60	59	47	60	0	30	31	0	37	60	60
Witta, 2012	Entinostat+Erlotinib	67	66	39	1	55		18	8	56	66	64
Witta, 2012	Erlotinib	65	67	43	2	55		21	9	54	64	62
WJOG 5108L, 2016	Gefitinib	279	68	127	279	0	193	0	17	138	199	76
WJOG 5108L, 2016	Erlotinib	280	67	128	280	0	194	0	21	139	193	82
ZEAL, 2011	Pemetrexed+Vandetanib	256	59	159	28	197	219	54	18	199	217	256
ZEAL, 2011	Pemetrexed	278	60	171	34	218	232	60	13	224	240	278
ZEST, 2011	Erlotinib	617	61	393	207	388	519	143	77	472	391	617
ZEST, 2011	Vandetanib	623	60	381	202	401	517	129	65	493	404	623
Zhang, 2015	Erlotinib	43	55	24	43	0		6	2	31	43	43
Zhang, 2015	Nab-Paclitaxel+Erlotinib	45	55	23	45	0		7	3	35	45	45
ZODIAC, 2010	Docetaxel+Vandetanib	694	59	497	259	410	598	184	6	536	694	662
ZODIAC, 2010	Docetaxel	697	58	473	252	417	590	160	2	524	697	679

Trials	Treatment	Sample size	Age	Male	Asian	Caucasian	Stage IV	Squamous	PS2	Smokers	Second line	EGFR-WT or unknown [‡]
<i>East Asia S-1 Trial in Lung Cancer, 2017</i>	<i>S-1</i>	<i>577</i>	<i>62</i>	<i>388</i>	<i>573</i>	<i>4</i>	<i>528</i>	<i>105</i>	<i>12</i>	<i>395</i>	<i>350</i>	<i>442</i>
<i>East Asia S-1 Trial in Lung Cancer, 2018</i>	<i>Docetaxel</i>	<i>577</i>	<i>62</i>	<i>381</i>	<i>566</i>	<i>4</i>	<i>535</i>	<i>97</i>	<i>13</i>	<i>390</i>	<i>357</i>	<i>440</i>
<i>Fandi, 2018</i>	<i>CC-486 + Pembrolizumab</i>	<i>51</i>	<i>63</i>	<i>26</i>	<i>0</i>	<i>42</i>	<i>49</i>	<i>10</i>	<i>0</i>	<i>51</i>	<i>51</i>	<i>51</i>
<i>Fandi, 2018</i>	<i>Placebo + Pembrolizumab</i>	<i>49</i>	<i>65</i>	<i>31</i>	<i>1</i>	<i>45</i>	<i>48</i>	<i>8</i>	<i>0</i>	<i>49</i>	<i>49</i>	<i>49</i>
<i>SELECT-2, 2017</i>	<i>Selumetinib + docetaxel 75</i>	<i>84</i>	<i>60</i>	<i>58</i>	<i>0</i>	<i>78</i>			<i>0</i>	<i>75</i>	<i>84</i>	<i>84</i>
<i>SELECT-2, 2017</i>	<i>Placebo + docetaxel 75</i>	<i>43</i>	<i>64</i>	<i>27</i>	<i>0</i>	<i>41</i>			<i>0</i>	<i>40</i>	<i>43</i>	<i>43</i>
<i>Wu, 2017</i>	<i>Nab-paclitaxel</i>	<i>46</i>	<i>58</i>	<i>24</i>	<i>46</i>	<i>0</i>		<i>8</i>	<i>17</i>	<i>42</i>	<i>46</i>	<i>46</i>
<i>Wu, 2017</i>	<i>Placebo</i>	<i>46</i>	<i>57</i>	<i>26</i>	<i>46</i>	<i>0</i>		<i>11</i>	<i>13</i>	<i>43</i>	<i>46</i>	<i>46</i>
<i>Yu, 2018</i>	<i>Apatinib + Chemotherapy</i>											
<i>Yu, 2018</i>	<i>Chemotherapy</i>											
<i>JAVELIN, 2018</i>	<i>Avelumab</i>	<i>396</i>	<i>64</i>	<i>269</i>	<i>102</i>	<i>294</i>	<i>373</i>	<i>120</i>	<i>0</i>	<i>326</i>	<i>351</i>	<i>385</i>
<i>JAVELIN, 2018</i>	<i>Docetaxel</i>	<i>396</i>	<i>63</i>	<i>273</i>	<i>114</i>	<i>282</i>	<i>370</i>	<i>122</i>	<i>0</i>	<i>333</i>	<i>353</i>	<i>383</i>
CHECKMATE 078, 2019	Nivolumab	338	59	263	308	30		133	0	236	337	338
CHECKMATE 078, 2019	Docetaxel	166	59	134	151	15		67	1	118	165	166
Sequist, 2019	Seribantumab +erlotinib	87	63	50	7	74	76	22		75		87
Sequist, 2019	erlotinib	45	64	27	6	36	39	4		33		45
NCT03023423, 2019	Daratumumab + Atezolizumab	46	63	38	0	41			1			46
NCT03023423, 2019	Azeulizumab	46	62	28	0	35			0			46
Lung-MAP S14001,2019	Ipilimumab + Nivolumab	125					125	125				125
Lung-MAP S14001,2019	Nivolumab	127					127	127				127

* Trials in which patients in the control arm received chemotherapy (e.g., docetaxel or pemetrexed) at the investigators' discretion;

[‡]During the trial, some patients have been detected for EGFR mutation so we provided the number of patients excluding patients identified EGFR positive

In **blue italic bold** are the results of the 2018 update

In **dark red italic bold** are the results of the 2019 update

